Platelet Glycoprotein GPIIb-IIIa Complex
"Platelet Glycoprotein GPIIb-IIIa Complex" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Platelet membrane glycoprotein complex important for platelet adhesion and aggregation. It is an integrin complex containing INTEGRIN ALPHAIIB and INTEGRIN BETA3 which recognizes the arginine-glycine-aspartic acid (RGD) sequence present on several adhesive proteins. As such, it is a receptor for FIBRINOGEN; VON WILLEBRAND FACTOR; FIBRONECTIN; VITRONECTIN; and THROMBOSPONDINS. A deficiency of GPIIb-IIIa results in GLANZMANN THROMBASTHENIA.
| Descriptor ID |
D019039
|
| MeSH Number(s) |
D12.776.395.550.625.785 D12.776.543.550.625.785 D12.776.543.750.705.408.460.700 D12.776.543.750.705.675.784
|
| Concept/Terms |
Platelet Glycoprotein GPIIb-IIIa Complex- Platelet Glycoprotein GPIIb-IIIa Complex
- Platelet Glycoprotein GPIIb IIIa Complex
- Glycoproteins IIb-IIIa
- Glycoproteins IIb IIIa
- Integrin alpha-IIb beta-3
- Integrin alpha IIb beta 3
- beta-3, Integrin alpha-IIb
- Integrin alphaIIbbeta3
- alphaIIbbeta3, Integrin
- GPIIb-IIIa Receptors
- GPIIb IIIa Receptors
- Receptors, GPIIb-IIIa
|
Below are MeSH descriptors whose meaning is more general than "Platelet Glycoprotein GPIIb-IIIa Complex".
Below are MeSH descriptors whose meaning is more specific than "Platelet Glycoprotein GPIIb-IIIa Complex".
This graph shows the total number of publications written about "Platelet Glycoprotein GPIIb-IIIa Complex" by people in this website by year, and whether "Platelet Glycoprotein GPIIb-IIIa Complex" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 1 | 1 |
| 2001 | 1 | 1 | 2 |
| 2002 | 8 | 1 | 9 |
| 2003 | 7 | 2 | 9 |
| 2004 | 6 | 5 | 11 |
| 2005 | 3 | 1 | 4 |
| 2006 | 5 | 7 | 12 |
| 2007 | 3 | 2 | 5 |
| 2008 | 2 | 0 | 2 |
| 2009 | 1 | 2 | 3 |
| 2011 | 3 | 1 | 4 |
| 2012 | 3 | 2 | 5 |
| 2013 | 1 | 1 | 2 |
| 2015 | 1 | 1 | 2 |
| 2016 | 1 | 0 | 1 |
| 2017 | 1 | 2 | 3 |
| 2018 | 1 | 0 | 1 |
| 2019 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Platelet Glycoprotein GPIIb-IIIa Complex" by people in Profiles.
-
Platelet Activation by Antiphospholipid Antibodies Depends on Epitope Specificity and is Prevented by mTOR Inhibitors. Thromb Haemost. 2019 Jul; 119(7):1147-1153.
-
Characteristics and outcomes of patients requiring bailout use of glycoprotein IIb/IIIa inhibitors for thrombotic complications of percutaneous coronary intervention: An analysis from the CHAMPION PHOENIX trial. Int J Cardiol. 2019 Mar 01; 278:217-222.
-
Evaluation of Ischemic and Bleeding Risks Associated With 2 Parenteral Antiplatelet Strategies Comparing Cangrelor With Glycoprotein IIb/IIIa Inhibitors: An Exploratory Analysis From the CHAMPION Trials. JAMA Cardiol. 2017 02 01; 2(2):127-135.
-
Cangrelor With and Without Glycoprotein?IIb/IIIa Inhibitors in?Patients?Undergoing Percutaneous?Coronary Intervention. J Am Coll Cardiol. 2017 Jan 17; 69(2):176-185.
-
Fasting glucose, NT-proBNP, treatment with eptifibatide, and outcomes in non-ST-segment elevation acute coronary syndromes: An analysis from EARLY ACS. Int J Cardiol. 2017 Apr 01; 232:264-270.
-
Impact of glycoprotein IIb/IIIa inhibitors on the efficacy and safety of ticagrelor compared with clopidogrel in patients with acute coronary syndromes: Analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial. Am Heart J. 2016 Jul; 177:1-8.
-
Frequency, clinical and angiographic characteristics, and outcomes of high-risk non-ST-segment elevation acute coronary syndromes patients with left circumflex culprit lesions. Int J Cardiol. 2016 Jan 15; 203:708-13.
-
Glycoprotein IIb/IIIa Receptor Inhibitors in Combination With Vorapaxar, a Platelet Thrombin Receptor Antagonist, Among Patients With Non-ST-Segment Elevation Acute Coronary Syndromes (from the TRACER Trial). Am J Cardiol. 2015 May 15; 115(10):1325-32.
-
Association between bleeding and mortality among women and men with high-risk acute coronary syndromes: insights from the Early versus Delayed, Provisional Eptifibatide in Acute Coronary Syndromes (EARLY ACS) trial. Am Heart J. 2013 Oct; 166(4):723-8.
-
Routine early eptifibatide versus delayed provisional use at percutaneous coronary intervention in high-risk non-ST-segment elevation acute coronary syndromes patients: an analysis from the Early Glycoprotein IIb/IIIa Inhibition in Non-ST-Segment Elevation Acute Coronary Syndrome trial. Am Heart J. 2013 Sep; 166(3):466-73.